Moreover, CRC cells harboring MRE11 deficiencies are more sensitive to PARP inhibitors [103], platinum salts [97], and 5-fluorouracil/leucovorin/ irinotecan combination [96]. Here, PARP1 is linked to colorectal carcinoma.